Market Overview

Research and Markets: Celiac Disease - Pipeline Review, H1 2012 - Latest News and Deals Relating to the Products

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/4a81d41c/celiac_disease_p) has announced the addition of Global Markets Direct's new report "Celiac Disease - Pipeline Review, H1 2012" to their offering.

Global Markets Direct's, 'Celiac Disease - Pipeline Review, H1 2012', provides an overview of the Celiac Disease therapeutic pipeline. This report provides information on the therapeutic development for Celiac Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Celiac Disease. 'Celiac Disease - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- A snapshot of the global therapeutic scenario for Celiac Disease.

- A review of the Celiac Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Celiac Disease pipeline on the basis of route of administration and molecule type.

- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.

- Key discontinued pipeline projects.

- Latest news and deals relating to the products.

Key Topics Covered:

  • List of Tables
  • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
  • Celiac Disease Overview
  • Therapeutics Development
  • An Overview of Pipeline Products for Celiac Disease
  • Celiac Disease Therapeutics under Development by Companies
  • Celiac Disease Therapeutics under Investigation by Universities/Institutes
  • Mid Clinical Stage Products
  • Comparative Analysis
  • Early Clinical Stage Products
  • Comparative Analysis
  • Discovery and Pre-Clinical Stage Products
  • Comparative Analysis
  • Celiac Disease Therapeutics - Products under Development by Companies
  • Celiac Disease Therapeutics - Products under Investigation by Universities/Institutes
  • Companies Involved in Celiac Disease Therapeutics Development
  • Celiac Disease - Therapeutics Assessment
  • Assessment by Monotherapy Products
  • Assessment by Combination Products
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Drug Profiles
  • Celiac Disease Therapeutics - Drug Profile Updates
  • Celiac Disease Therapeutics - Dormant Products
  • Celiac Disease - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us

Disclaimer

Companies Mentioned:

  • BioLineRx, Ltd.
  • Alba Therapeutics Corporation
  • ActogeniX NV
  • Artielle ImmunoTherapeutics, Inc.
  • Altor BioScience Corporation
  • Alvine Pharmaceuticals, Inc.
  • Avaxia Biologics, Inc.

For more information visit http://www.researchandmarkets.com/research/4a81d41c/celiac_disease_p

Source: Global Markets Direct

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): 353-1-481-1716
Sector: Immune Disorders

 

Around the Web, We're Loving...

Get Benzinga's Newsletters